Military Medical Unit-Slovenian Army, 1000 Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Int J Mol Sci. 2023 Dec 22;25(1):190. doi: 10.3390/ijms25010190.
Calretinin is a promising diagnostic biomarker for malignant mesothelioma (MM), but less is known about its prognostic role. Our aim was to evaluate the association between serum calretinin concentration or genetic factors and the survival or outcome of cisplatin-based chemotherapy in MM. Our study included 265 MM patients. Serum calretinin concentration was determined using ELISA. Patients were genotyped for seven polymorphisms in , , , , and using competitive allele-specific PCR. Nonparametric tests, logistic regression, and survival analysis were used for statistical analysis. Higher serum calretinin concentration was associated with shorter progression-free (PFS) (HR = 1.18 (1.02-1.37), = 0.023) and overall survival (OS) (HR = 1.20 (1.03-1.41), = 0.023), but the association was not significant after adjusting for clinical factors (HR = 1.05 (0.85-1.31), = 0.653 and HR = 1.06 (0.84-1.34), = 0.613, respectively). rs3801339 and rs3807348 were associated with survival even after adjustment (HR = 1.76 (1.17-2.64), = 0.007 and HR = 0.65 (0.45-0.95), = 0.028, respectively). Calretinin concentration was higher in patients who progressed after treatment with cisplatin-based chemotherapy (1.68 vs. 0.45 ng/mL, = 0.001). Calretinin concentration above 0.89 ng/mL was associated with shorter PFS and OS from the start of chemotherapy (HR = 1.88 (1.28-2.77), = 0.001 and HR = 1.91 (1.22-2.97), = 0.004, respectively), even after adjusting for clinical factors ( < 0.05). rs3807348 was associated with a better response to chemotherapy (OR = 2.69 (1.17-6.18), = 0.020). We showed that serum calretinin is associated with survival and chemotherapy treatment outcomes in MM and could serve as a predictive biomarker.
钙结合蛋白是恶性间皮瘤（MM）有前途的诊断生物标志物，但关于其预后作用的了解较少。我们的目的是评估血清钙结合蛋白浓度或遗传因素与 MM 基于顺铂的化疗的生存或结果之间的关联。我们的研究包括 265 名 MM 患者。使用 ELISA 测定血清钙结合蛋白浓度。使用竞争性等位基因特异性 PCR 对 、 、 、 和 中的七个多态性对患者进行基因分型。使用非参数检验、逻辑回归和生存分析进行统计分析。较高的血清钙结合蛋白浓度与较短的无进展生存期（PFS）（HR = 1.18（1.02-1.37）， = 0.023）和总生存期（OS）（HR = 1.20（1.03-1.41）， = 0.023）相关，但在调整临床因素后，相关性不显著（HR = 1.05（0.85-1.31）， = 0.653 和 HR = 1.06（0.84-1.34）， = 0.613，分别）。即使在调整后，rs3801339 和 rs3807348 与生存相关（HR = 1.76（1.17-2.64）， = 0.007 和 HR = 0.65（0.45-0.95）， = 0.028，分别）。与顺铂为基础的化疗后进展的患者相比，钙结合蛋白浓度更高（1.68 vs. 0.45 ng/mL， = 0.001）。化疗开始时，钙结合蛋白浓度高于 0.89 ng/mL 与较短的 PFS 和 OS 相关（HR = 1.88（1.28-2.77）， = 0.001 和 HR = 1.91（1.22-2.97）， = 0.004，分别），即使在调整临床因素后也是如此（ < 0.05）。rs3807348 与化疗反应相关（OR = 2.69（1.17-6.18）， = 0.020）。我们表明，血清钙结合蛋白与 MM 的生存和化疗治疗结果相关，可作为预测生物标志物。
